company background image
CNW

co.don XTRA:CNW Stock Report

Last Price

€0.58

Market Cap

€15.5m

7D

41.5%

1Y

-77.3%

Updated

10 Aug, 2022

Data

Company Financials +
CNW fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance0/6
Financial Health3/6
Dividends0/6

CNW Stock Overview

co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide.

co.don Competitors

Price History & Performance

Summary of all time highs, changes and price drops for co.don
Historical stock prices
Current Share Price€0.58
52 Week High€2.56
52 Week Low€0.25
Beta1.47
1 Month Change-11.59%
3 Month Change-41.41%
1 Year Change-77.34%
3 Year Change-92.35%
5 Year Change-96.63%
Change since IPO-99.05%

Recent News & Updates

Shareholder Returns

CNWDE BiotechsDE Market
7D41.5%-2.1%0.6%
1Y-77.3%-4.1%-20.0%

Return vs Industry: CNW underperformed the German Biotechs industry which returned -3% over the past year.

Return vs Market: CNW underperformed the German Market which returned -20.8% over the past year.

Price Volatility

Is CNW's price volatile compared to industry and market?
CNW volatility
CNW Average Weekly Movement32.7%
Biotechs Industry Average Movement8.7%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.4%
10% least volatile stocks in DE Market2.8%

Stable Share Price: CNW is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 33% a week.

Volatility Over Time: CNW's weekly volatility has increased from 19% to 33% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993134Tilmann Burhttps://www.codon.de

co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons.

co.don Fundamentals Summary

How do co.don's earnings and revenue compare to its market cap?
CNW fundamental statistics
Market Cap€15.50m
Earnings (TTM)-€9.32m
Revenue (TTM)€9.80m

1.6x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CNW income statement (TTM)
Revenue€9.80m
Cost of Revenue€1.85m
Gross Profit€7.96m
Other Expenses€17.28m
Earnings-€9.32m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 30, 2022

Earnings per share (EPS)-0.35
Gross Margin81.18%
Net Profit Margin-95.09%
Debt/Equity Ratio22.8%

How did CNW perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CNW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CNW?

Other financial metrics that can be useful for relative valuation.

CNW key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA-2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CNW's PS Ratio compare to its peers?

CNW PS Ratio vs Peers
The above table shows the PS ratio for CNW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.5x
MDG1 Medigene
5.8x1.6%€60.2m
PA8 Paion
9.4x43.1%€66.9m
ECX Epigenomics
1.2x43.4%€7.5m
VSCA 4SC
1.7xn/a€30.5m
CNW co.don
1.6x28.3%€15.5m

Price-To-Sales vs Peers: CNW is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (4.5x).


Price to Earnings Ratio vs Industry

How does CNW's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Sales vs Industry: CNW is good value based on its Price-To-Sales Ratio (1.6x) compared to the German Biotechs industry average (5.8x)


Price to Sales Ratio vs Fair Ratio

What is CNW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CNW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ratio13.2x

Price-To-Sales vs Fair Ratio: CNW is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).


Share Price vs Fair Value

What is the Fair Price of CNW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CNW (€0.58) is trading below our estimate of fair value (€21.82)

Significantly Below Fair Value: CNW is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is co.don forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


96.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNW is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).

Earnings vs Market: CNW is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CNW is expected to become profitable in the next 3 years.

Revenue vs Market: CNW's revenue (28.3% per year) is forecast to grow faster than the German market (4.7% per year).

High Growth Revenue: CNW's revenue (28.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CNW's Return on Equity is forecast to be very high in 3 years time (43.7%).


Discover growth companies

Past Performance

How has co.don performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-19.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CNW is currently unprofitable.

Growing Profit Margin: CNW is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CNW is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.

Accelerating Growth: Unable to compare CNW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).


Return on Equity

High ROE: CNW has a negative Return on Equity (-53.07%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is co.don's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CNW's short term assets (€9.5M) exceed its short term liabilities (€3.0M).

Long Term Liabilities: CNW's short term assets (€9.5M) exceed its long term liabilities (€5.8M).


Debt to Equity History and Analysis

Debt Level: CNW has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CNW's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CNW has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CNW has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is co.don current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CNW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CNW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNW's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CNW has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.9yrs

Average board tenure


CEO

Tilmann Bur (57 yo)

3.17yrs

Tenure

€292,000

Compensation

Mr. Tilmann Bur has been the Member of Executive Board of co.don AG since June 1, 2019 and serves as its Chief Executive Board and served as its Chief Operating Officer until January 2020. Mr. Bur is an in...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Tilmann's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Tilmann's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: CNW's board of directors are considered experienced (9.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.2%.


Top Shareholders

Company Information

co.don AG's employee growth, exchange listings and data sources


Key Information

  • Name: co.don AG
  • Ticker: CNW
  • Exchange: XTRA
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €15.500m
  • Shares outstanding: 26.72m
  • Website: https://www.codon.de

Number of Employees


Location

  • co.don AG
  • Warthestraße 21
  • Teltow
  • Brandenburg
  • 14513
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/08/10 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.